Abstract 1382
Background
Glioblastoma (GBM) is well known as the most common primary aggressive malignant brain tumor of the CNS and became one of the most lethal forms of cancer in human. The prognosis for patients with GBM is very poor. Current treatment options for recurrent GBM are very limited. Apatinib, a novel small molecular anti-angiogenic inhibitor, can highly selectively bind VEGFR-2 and inhibit its activation to block VEGF mediated the signal transduction and inhibit the angiogenesis to control the growth of the tumors. We hypothesized that apatinib combined with dose-dense TMZ could lead to prolonged 6-month PFS and/or OS. We also assessed toxicity and tolerability.
Methods
Patients with recurrent glioblastoma were enrolled in this study. Patients were treated with concurrent treatment of apatinib (500mg qd) and dose-dense temozolomide (100 mg/m2 , 7 days on with 7 days off ) until disease progression or intolerable toxicity. The efficacy was evaluated using RANO high-grade glioma criteria. The safety was assessed via NCI-CTCAE 4.0. Survival was estimated with Kaplan-Meier curve and log-rank test.
Results
From March 2016 to January 2018, twenty eligible patients who had relapsed from the standard chemoradiotherapy regimen were enrolled in this study. 35% were female and the median ages were 50.5 years. The median KPS score before treatment was 70. Median follow-up time was 12 months. KPS scores improved in 60%(12/20) of patients after treatment. In total, there were 1 with CR, 8 with PR, 9 with SD, and 2 with PD. Three patients were still alive. The ORR was 45% (9/20) and the DCR was 90% (18/20). The median PFS for all patients were 6 months (95% confidence interval [CI]: 5.3m to 7.8m). Median OS is 9.3 months (95% CI, 8.2m–12.2m). The most common treatment-related adverse events (AEs) were hypertension (20.9%), hand-foot syndrome (16.3%), leukopenia (14.0%), The grade 3/4 adverse events included hypertension (4.7%), leukopenia (2.3%), thrombocytopenia (2.3%).
Conclusions
Apatinib combined with dose-dense temozolomide seems to be a promising therapeutic option for recurrent glioblastoma with acceptable toxicity profiles. Clinical randomized controlled trial is warranted to be designed to confirm the results.
Clinical trial identification
NCT03660761.
Editorial acknowledgement
Baoyan Liu (Shandong Medical Biotechnological Center, School of Medicine and Life Science, Shandong Academy of Medical Sciences, University of Jinan) provided assistance with manuscript editing.
Legal entity responsible for the study
Shandong Cancer Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4883 - A New Population Model Validated Pharmacokinetic Similarity of HLX01 and Rituximab in B-Cell Lymphoma
Presenter: Yuankai Shi
Session: Poster Display session 1
Resources:
Abstract
4908 - Efficacy of salvage therapy in the treatment of Helicobacter pylori-positive gastric low-grade mucosa-associated lymphoid tissue lymphoma
Presenter: Sung-Nam Lim
Session: Poster Display session 1
Resources:
Abstract
2360 - Mutational analysis of extranodal marginal zone lymphoma using next generation sequencing
Presenter: Seok Jae Huh
Session: Poster Display session 1
Resources:
Abstract
2430 - Clinical features, treatment and outcomes of colon and rectum mucosa-associated lymphoid tissue (MALT) lymphoma: Literature reviews published in English between 1993 and 2017
Presenter: Jeong Yeon Kim
Session: Poster Display session 1
Resources:
Abstract
4654 - Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 52 patients
Presenter: Guldane Cengiz Seval
Session: Poster Display session 1
Resources:
Abstract
1732 - Safety and efficacy of Bendamustine and Rituximab (BR) regimen in Indian Chronic Lymphocytic Leukemia patients
Presenter: Ajay Gogia
Session: Poster Display session 1
Resources:
Abstract
5784 - N-terminal B-type natriuretic peptide (NT-proBNP) as an independed prognostic marker for patients with newly diagnosed multiple myeloma complicated by dialysis-dependent renal failure
Presenter: Sergey Semochkin
Session: Poster Display session 1
Resources:
Abstract
836 - The first-line effect of Bortezomib-based Therapy on Clinical Outcomes for Taiwanese Patients with multiple myeloma
Presenter: Ching-Liang Ho
Session: Poster Display session 1
Resources:
Abstract
2085 - Impact of Donor Lymphocyte Infusion in Relapsing Myeloid Neoplasms Post Allogeneic Hematopoietic Stem Cell Transplantation
Presenter: Hanafy Hafez
Session: Poster Display session 1
Resources:
Abstract
6079 - Invasive fungal diseases in patients with Hodgkin’s lymphoma before and after allogeneic hematopoietic stem cell transplantation
Presenter: Marina Popova
Session: Poster Display session 1
Resources:
Abstract